AXL表达与乳腺癌预后及临床病理特征关系的Meta分析

doi:10.3969/j.issn.1674-490X.2020.03.003

摘要/Abstract

摘要： 目的探讨受体酪氨酸激酶AXL蛋白的表达对乳腺癌患者预后及临床病理特征的意义。方法在中国知网(CNKI)、万方医学网(Wanfang Data)、 Cochrane Library、Embase、PubMed和Medline数据库中,搜索国内外公开发表的有关AXL与乳腺癌预后关系的文献,检索时限均为从建库至2019年10月。2位研究者按纳入和排除标准独立筛选文献、提取资料和评价纳入研究的偏倚风险,并进行Meta分析。结果共纳入7篇文献,包括933例乳腺癌患者。AXL高表达组的乳腺癌患者总生存期(overall survival,OS)明显低于低表达组(HR=2.36,95%CI 1.60~3.46,P<0.000 1),但其表达在无复发生存期(relapse free survival,RFS)和无疾病生存期(disease free survival,DFS)中差异无统计学意义,且与乳腺癌的年龄、临床分期、组织分级、淋巴结转移及受体表达的相关性分析无统计学意义。结论 AXL的阳性表达与乳腺癌患者预后不良有关,是乳腺癌个体化治疗的潜在分子标志物。

关键词: AXL, 乳腺癌, Meta分析, 预后

Abstract: Objective To evaluate the prognostic and clinicopathological significance of AXL expression in breast cancer tissues by meta-analysis. Methods Such databases as CNKI, Wanfang Data, Cochrane Library, Embase, PubMed and Medline were searched for the studies on the prognostic value of AXL expression in breast cancer from inception to October 2019. Two researchers independently screened eligible literature, extracted data and evaluate the risk of bias of included studies to analyze the data. Results Seven studies involving 933 patients were included. It was shown that,the higher AXL expression group had a shorter overall survival than that of the lower AXL expression group(HR=2.36, 95%CI 1.60-3.46, P<0.000 1). However,there was no significant difference between two group in relapse free survival and disease free survival. It was shown that the expression of AXL was not associated with age, clinical stages, histologic grade, lymph node metastasis or receptor expression. Conclusion The meta-analysis suggests that AXL positive expression is associated with worse survival in patients. It will be a protential molecular marker for individualized treatment of breast cancer.

Key words: AXL, breast cancer, meta-analysis, prognosis

中图分类号:

李娜,宋若飘,贾友超,臧爱民. AXL表达与乳腺癌预后及临床病理特征关系的Meta分析[J]. 医学研究与教育, 2020, 37(3): 18-27.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2] WAZIR U, MOKBEL L, WAZIR A, et al. Optimizing adjuvant endocrine therapy for early ER+ breast cancer: an update for surgeons[J]. Am J Surg, 2019, 217(1): 152-155. DOI: 10.1016/j.amjsurg.2018.07.052.
[3] DERAKHSHANI A, REZAEI Z, SAFARPOUR H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy[J]. J Cell Physiol, 2020, 235(4): 3142-3156. DOI: 10.1002/jcp.29216.
[4] WATERHOUSE M P, UGUR R, KHALED W T. Therapeutic and mechanistic perspectives of protein complexes in breast cancer[J]. Front Cell Dev Biol, 2019, 7: 335. DOI: 10.3389/fcell.2019.00335.
[5] HILL D P, HARPER A, MALCOLM J, et al. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance[J]. BMC Cancer, 2019, 19: 1039. DOI: 10.1186/s12885-019-6278-9.
[6] LECONET W, CHENTOUF M, DU MANOIR S, et al. Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis[J]. Clin Cancer Res, 2017, 23(11): 2806-2816. DOI: 10.1158/1078-0432.CCR-16-1316.
[7] LIU L, GREGER J, SHI H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL[J]. Cancer Res, 2009, 69(17): 6871-6878. DOI: 10.1158/0008-5472.CAN-08-4490.
[8] MENDEL D B, LAIRD A D, XIN X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003, 9(1): 327-337. DOI: 10.1038/s41598-017-18120-4.
[9] YU W, GE X, LAI X, et al. The up-regulation of Axl is associated with a poor prognosis and promotes proliferation in pancreatic ductal adenocarcinoma[J]. Int J Clin Exp Pathol, 2019, 12: 1626.
[10] KARACHALIOU N, CHAIB I, CARDONA A F, et al. Common co-activation of AXL and CDCP1 in EGFR-mutation-positive non-small cell lung cancer associated with poor prognosis[J]. EbioMedicine, 2018, 29: 112-127. DOI: 10.1016/j.ebiom.2018.02.001.
[11] HSU C C, HSIEH P M, CHEN Y S, et al. Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection[J]. Cancer Med, 2019, 8(7): 3453-3463. DOI: 10.1002/cam4.2229.
[12] WELLS G A, SHEA B, O'CONNELL D, et al. The Newcastle-Ottawa Scale(NOS)for assessing the quality if nonrandomized studies in metaanalyses[EB/OL].(2015-07-21)[2019-10-01]. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.htm.
[13] TANAKA K, TOKUNAGA E, INOUE Y, et al. Impact of expression of vimentin and Axl in breast cancer[J]. Clin Breast Cancer, 2016, 16(6): 520-526. DOI: 10.1016/j.clbc.2016.06.015.
[14] GJERDRUM C, TIRON C, HOIBY T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival[J]. Proc Natl Acad Sci U S A, 2010, 107(3): 1124-1129. DOI: 10.1073/pnas.0909333107.
[15] BOTTAI G, RASCHIONI C, SZÉKELY B, et al. AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients[J]. NPJ Breast Cancer, 2016, 2: 16033. DOI: 10.1038/npjbcancer.2016.33.
[16] JIN G, WANG Z, WANG J, et al. Expression of Axl and its prognostic significance in human breast cancer[J]. Oncol Lett, 2017, 13(2): 621-628. DOI: 10.3892/ol.2016.5524.
[17] DINE J L, O’SULLIVAN C C, VOELLER D, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl[J]. Breast Cancer Res Treat, 2016, 155(2): 235-251. DOI: 10.1007/s10549-015-3673-z.
[18] 周萍, 王莉, 黄一凡, 等. 乳腺浸润性导管癌中Axl蛋白的表达及意义[J]. 临床与实验病理学杂志, 2017, 33(11): 1263-1266. DOI: 10.13315/j.cnki.cjcep.2017.11.021.
[19] WANG C, JIN H, WANG N, et al. Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β-catenin signaling[J]. Theranostics, 2016, 6(8): 1205-1219. DOI: 10.7150/thno.15083.
[20] PACCEZ J D, VOGELSANG M, PARKER M I, et al. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications[J]. Int J Cancer, 2014, 134(5): 1024-1033. DOI: 10.1002/ijc.28246.
[21] ZHU C, WEI Y, WEI X. Axl receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications[J]. Mol Cancer, 2019, 18: 153. DOI: 10.1186/s12943-019-1090-3.
[22] HONG J, MAACHA S, BELKHIRI A. Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma[J]. Mol Oncol, 2018, 12(12): 2191-2208. DOI: 10.1002/1878-0261.12395.
[23] CRUZ V H, ARNER E N, DU W, et al. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer[J]. JCI Insight, 2019, 4(9): e126117. DOI: 10.1172/jci.insight.126117.
[24] IIDA K, SAKAI R, YOKOYAMA S, et al. Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXLl[J]. Sci Rep, 2017, 7: 17770. DOI: 10.1038/s41598-017-18120-4.
[25] COLAVITO S A. AXL as a Target in Breast Cancer Therapy[J]. J Oncol, 2020, 2020: 5291952-5291958. DOI: 10.1155/2020/5291952.
[26] ZHANG S, XU X S, YANG J X, et al. The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review[J]. Onco Targets Ther, 2018, 11: 509-519. DOI: 10.2147/OTT.S150952.
[27] KIM J E, LEUNG E, BAGULEY B C, et al. Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines[J]. Front Genet, 2013, 4: 97-105. DOI: 10.3389/fgene.2013.00097.
[28] ZAJAC O, LECLERE R, NICOLAS A, et al. AXL controls directed migration of mesenchymal triple-negative breast cancer cells[J]. Cells, 2020, 9(1): 247. DOI: 10.3390/cells9010247.
[29] BERCLAZ G, ALTERMATT H J, ROHRBACH V, et al. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast[J]. Ann Oncol, 2001, 12(6): 819-824. DOI: 10.1023/a:1011126330233.